Through 2022, Growth in the Neuropathic Pain Drug Market Will be Constrained by the Genericization of Sales-Leading Agents from Eli Lilly/Shionogi, Endo/Grunenthal and Pfizer

Neuropathic Back Pain Continues to Account for the Largest Segment of the Neuropathic Pain Market, According to a New Report from Decision Resources

Nov 04, 2013, 09:00 ET from Decision Resources

BURLINGTON, Mass., Nov. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the loss of U.S. and European market exclusivity of three sales-leading neuropathic pain (NP) agents—Eli Lilly/Shionogi's Cymbalta/Xeristar, Endo/Grunenthal's Lidoderm/Versatis and Pfizer's Lyrica—combined with a lack of transformative emerging therapies forecasted to launch specifically for NP, will contribute to a slight market decline during the 2012-2022 study period. Nevertheless, the launch of several high priced, branded agents that will experience uptake in niche populations within the NP market will help to counterbalance some of the sales lost to generic erosion. Consequently, in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, combined NP market sales will decrease from $6.3 billion in 2012 to less than $6 billion in 2022.

(Logo: )

The Pharmacor report entitled Neuropathic Pain also reveals that neuropathic back pain continues to account for the largest segment of the NP market—over 40 percent market share in 2012. Other segments with notable market share include painful diabetic neuropathy and postsurgical/post-traumatic NP. Postherpetic neuralgia, neuropathic cancer pain and central NP are among the more active areas of NP drug development; however, they represented much smaller segments of the overall NP market in 2012.

The report also finds that one of the greatest unmet needs in NP is a better understanding of the pathophysiology of the disease. Interviewed thought leaders note that existing knowledge gaps hamper both current medical practice and drug development.

"Neuropathic pain has and will continue to be characterized by significant heterogeneity in its underlying pathophysiological mechanisms, patient presentation of symptoms and patient responsiveness to therapy," said Decision Resources Principal Business Insights Analyst Andrea Buurma. "Greater knowledge of the pathological mechanisms that underlie neuropathic pain could lead to the identification of better drug targets and ultimately more-efficacious drug treatments. However, the recent failures of several promising agents in the late-stage pipeline, that were believed to act on mechanisms underlying pain, emphasize the challenge of developing drugs for this indication."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources